Table 1. Approved immune check point inhibitors.

Immunotherapy	Antibody target	Dose	Schedule
Nivolumab	PD-1 Ab*	240 mg IV	Q2 weeks
Pembrolizumab	PD-1 Ab*	200 mg IV	Q3 weeks
Atezolizumab	PD-L1 Ab**	1,200 mg IV	Q3 weeks

*, programmed death-1 antibody; **, programmed death ligand-1 antibody.